Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 11/20 | 0.76 |
| ▸ | OPRD1 | P41143 | 9/20 | 0.69 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.69 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.68 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.68 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.68 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.68 |
| ▸ | DRD2 | P14416 | 1/20 | 0.68 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.68 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.68 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.68 |
| ▸ | MAOA | P21397 | 1/20 | 0.68 |
| ▸ | DRD4 | P21917 | 1/20 | 0.68 |
| ▸ | MAOB | P27338 | 1/20 | 0.68 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.68 |
| ▸ | HRH1 | P35367 | 1/20 | 0.68 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.68 |
| ▸ | DRD3 | P35462 | 1/20 | 0.68 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.68 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4549608 | 0.92 | OPRM1 (0.81) | OPRM1OPRD1OPRK1SLC22A1NR1I2 | |
| SCHEMBL18623773 | 0.90 | OPRM1 (0.87) | OPRM1OPRD1OPRK1SLC22A1NR1I2 | |
| SCHEMBL28781766 | 0.90 | CHRM2 (0.74) | OPRM1OPRD1OPRK1CHRM3SIGMAR1 | |
| SCHEMBL18623766 | 0.88 | OPRM1 (0.75) | OPRM1OPRD1OPRK1SLC22A1NR1I2 | |
| SCHEMBL28781781 | 0.85 | OPRM1 (0.85) | OPRM1 | |
| SCHEMBL18623779 | 0.84 | OPRM1 (1.00) | OPRM1OPRD1OPRK1SLC22A1NR1I2 | |
| SCHEMBL4545375 | 0.83 | OPRM1 (0.81) | OPRM1OPRD1OPRK1SLC22A1NR1I2 | |
| SCHEMBL24726675 | 0.82 | OPRD1 (1.00) | OPRM1OPRD1OPRK1SLC22A1NR1I2 | |
| SCHEMBL1686075 | 0.82 | OPRM1 (0.92) | OPRM1OPRD1OPRK1SLC22A1NR1I2 | |
| SCHEMBL1172827 | 0.82 | OPRM1 (0.65) | OPRM1OPRD1OPRK1SLC22A1NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12529695-B2 | Fentanyl analogue detection methods and kits thereof | VERITEQUE USA, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| CN-118556058-A | New method | 细胞内治疗公司 | 2024-08-27 | — | — | CN | disclosed |
| US-20220390439-A1 | FENTANYL ANALOGUE DETECTION METHODS AND KITS THEREOF | VERITEQUE USA, INC. | 2022-12-08 | — | — | US | disclosed |
| US-20220390439-A1 | FENTANYL ANALOGUE DETECTION METHODS AND KITS THEREOF | VERITEQUE USA, INC. | 2022-12-08 | — | — | US | disclosed |
| US-20210093557-A1 | NASAL DRUG PRODUCTS AND METHODS OF THEIR USE | ADAPT PHARMA LTD (IE) | 2021-04-01 | — | — | US | disclosed |
| US-20200030229-A1 | NASAL DRUG PRODUCTS AND METHODS OF THEIR USE | Adapt Pharma Limited | 2020-01-30 | — | — | US | disclosed |
| US-20190015323-A1 | NASAL DRUG PRODUCTS AND METHODS OF THEIR USE | Adaph Pharma Limited | 2019-01-17 | — | — | US | disclosed |
| US-20170071851-A1 | NASAL DRUG PRODUCTS AND METHODS OF THEIR USE | INDIVIOR UK LIMITED (GB) | 2017-03-16 | — | — | US | disclosed |
| US-20170071851-A1 | NASAL DRUG PRODUCTS AND METHODS OF THEIR USE | INDIVIOR UK LIMITED (GB) | 2017-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170071851-A1 | NASAL DRUG PRODUCTS AND METHODS OF THEIR USE | OPRL1, OPRM1, OPRK1 | OPRM1 2/4885OPRD1 4/4885OPRK1 3/4885 |
| US-20210093557-A1 | NASAL DRUG PRODUCTS AND METHODS OF THEIR USE | OPRL1, OPRM1, OPRK1 | OPRM1 2/4885OPRD1 4/4885OPRK1 3/4885 |
| US-12529695-B2 | Fentanyl analogue detection methods and kits thereof | CA13, CA2, CA12 | OPRM1 24/4885OPRD1 6/4885OPRK1 19/4885 |
| US-20190015323-A1 | NASAL DRUG PRODUCTS AND METHODS OF THEIR USE | OPRL1, OPRM1, OPRK1 | OPRM1 2/4885OPRD1 4/4885OPRK1 3/4885 |
| US-20200030229-A1 | NASAL DRUG PRODUCTS AND METHODS OF THEIR USE | OPRL1, OPRM1, OPRK1 | OPRM1 2/4885OPRD1 4/4885OPRK1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.